Rhythm Pharmaceuticals Inc RYTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $38.11
- Day Range
- $37.65–39.04
- 52-Week Range
- $15.52–52.57
- Bid/Ask
- $37.70 / $37.83
- Market Cap
- $2.28 Bil
- Volume/Avg
- 159,627 / 585,133
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 226
- Website
- http://www.rhythmtx.com
Comparables
Valuation
|
Metric
|
RYTM
|
KROS
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 13.34 | 5.65 | 12.65 |
Price/Sales | 28.39 | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
RYTM
KROS
CBAY
Financial Strength
|
Metric
|
RYTM
|
KROS
|
CBAY
|
|---|---|---|---|
Quick Ratio | 5.27 | 13.63 | 10.70 |
Current Ratio | 5.58 | 14.25 | 10.96 |
Interest Coverage | −13.26 | — | −5.27 |
Quick Ratio
RYTM
KROS
CBAY
Profitability
|
Metric
|
RYTM
|
KROS
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −46.12% | −35.62% | −30.06% |
Return on Equity (Normalized) | −76.97% | −39.15% | −51.97% |
Return on Invested Capital (Normalized) | −76.40% | −41.95% | −30.87% |
Return on Assets
RYTM
KROS
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fbpcdxqvyr | Tdth | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xfyrssfh | Bwqzcl | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vkcyhhyk | Ckdygyv | $98.1 Bil | |
MRNA
| Moderna Inc | Nwbbffc | Vwnk | $39.1 Bil | |
ARGX
| argenx SE ADR | Qdjnnhhd | Jhjl | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Fnnklnxl | Npfr | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lpqlbllcs | Skjzkmd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zysntzk | Pxdyk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ccfggzxrk | Mzyfl | $12.5 Bil | |
INCY
| Incyte Corp | Gtmjfsmmp | Tyndtt | $11.9 Bil |